Half-dose influenza vaccine: Stretching the supply or wasting it?

Archives of Internal Medicine

Volumn 168, Issue 22, 2008, Pages 2402-2403

  Falsey, Ann R ^a  

^a ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG INDUSTRY; DRUG MANUFACTURE; EDITORIAL; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; PRIORITY JOURNAL; SEASONAL VARIATION; SERRATIA MARCESCENS; VACCINATION;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 58149090091     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.22.2402     Document Type: Editorial

References (17)

1. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza. recommendations of the advisory committee on immunization practices (ACIP), 2007. MMWR Recomm Rep. 2007;56(RR-6):1-54.
2. Mello MM, Brennan TA. Legal concerns and the influenza vaccine shortage. JAMA. 2005;294(14):1817-1820.
3. Meiklejohn G, Weiss DL, Shragg RI, Lennette EH. Evaluation of monovalent influenza virus vaccines, I: observations on antibody response following vaccination. Am J Hyg. 1952;55(1):1-11.
4. Masurel N, Laufer J. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg (Lond). 1984;92(3):263-276.
5. Gorse GJ, O'Connor TZ, Newman FK, et al. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis. 2004;190(1):11-19.
6. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35(1):69-75.
7. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 2004;103(1-2):133-138.
8. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767-777.
9. La Montagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis. 1983;5(4):723-736.
10. Treanor J, Keitel W, Belshe R, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20(7-8):1099-1105.
11. Cooper CL, Davis H, Cameron DW. Influenza vaccination with 1/10th the full dose. N Engl J Med. 2004;351(22):2339-2340.
12. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351(22):2295-2301.
13. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine. 2007;25(4):659-663.
14. Wyatt KN, Ryan GJ, Sheerin KA. Reduced-dose influenza vaccine. Ann Pharmacother. 2006;40(9):1635-1639.
15. Song JY, Ha SH, Kee SY, Jeong HW, Cheong HJ, Kim WJ. Debate on annual influenza vaccination in healthcare workers for the same subtype under the vaccine shortage. J Clin Virol. 2007;38(2):149-152.
16. Kramer JS, Durham C, Schroeder T, Garrelts JC. Effectiveness of half-dose versus full-dose influenza vaccine in health care workers. Am J Health Syst Pharm. 2006;63(21):2111-2115.
17. Engler RJM, Nelson MR, Klote MM, et al; Walter Reed Health Care System Influenza Vaccine Consortium. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008;168(22):2405-2414.